Shanghai Rightongene Biotechnology Co. Ltd. A
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of molecular diagnosis of infectious diseases in China. The company offers self-operated reagents, purchased preparations, scientific research services, and testing services for blood diseases, solid tumors, infectious diseases and lymphoma. Shanghai Rightongene Biotechnology Co., Ltd. was f… Read more
Market Cap & Net Worth: Shanghai Rightongene Biotechnology Co. Ltd. A (688217)
Shanghai Rightongene Biotechnology Co. Ltd. A (SHG:688217) has a market capitalization of $227.16 Million (CN¥1.67 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #17177 globally and #4487 in its home market, demonstrating a 4.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Rightongene Biotechnology Co. Ltd. A's stock price CN¥29.84 by its total outstanding shares 55855896 (55.86 Million).
Shanghai Rightongene Biotechnology Co. Ltd. A Market Cap History: 2021 to 2026
Shanghai Rightongene Biotechnology Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $551.08 Million to $227.16 Million (-23.10% CAGR).
Shanghai Rightongene Biotechnology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Rightongene Biotechnology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.58x
Shanghai Rightongene Biotechnology Co. Ltd. A's market cap is 0.58 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $551.08 Million | $290.95 Million | $47.33 Million | 1.89x | 11.64x |
| 2022 | $267.89 Million | $424.30 Million | $40.47 Million | 0.63x | 6.62x |
| 2023 | $272.38 Million | $258.21 Million | $7.93 Million | 1.05x | 34.35x |
| 2024 | $140.38 Million | $242.31 Million | -$15.76 Million | 0.58x | N/A |
Competitor Companies of 688217 by Market Capitalization
Companies near Shanghai Rightongene Biotechnology Co. Ltd. A in the global market cap rankings as of March 19, 2026.
Key companies related to Shanghai Rightongene Biotechnology Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Shanghai Rightongene Biotechnology Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Shanghai Rightongene Biotechnology Co. Ltd. A's market cap moved from $551.08 Million to $ 227.16 Million, with a yearly change of -23.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥227.16 Million | +13.24% |
| 2025 | CN¥200.59 Million | +42.90% |
| 2024 | CN¥140.38 Million | -48.46% |
| 2023 | CN¥272.38 Million | +1.68% |
| 2022 | CN¥267.89 Million | -51.39% |
| 2021 | CN¥551.08 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shanghai Rightongene Biotechnology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $227.16 Million USD |
| MoneyControl | $227.16 Million USD |
| MarketWatch | $227.16 Million USD |
| marketcap.company | $227.16 Million USD |
| Reuters | $227.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.